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Introduction-Pharmaceutical Innovation and Cost:
An American Dilemma
Mark Siegler, M.D.,* Alix Weisfeld,l and Richard A. Epstein, LL.B.*
The four papers which follow, presented during an interdisciplinary
symposium at the University of Chicago, respond to an atmosphere of growing
public dissatisfaction with the pharmaceutical industry. The industry's problems
include the rising cost of drugs, the slowing rate of innovation, concerns about
the FDA's ability to effectively regulate the safety and efficacy of drugs, and the
impact of the recently passed prescription drug benefit legislation. The past year
has seen a flood of new books cataloguing these problems, including Marcia
Angell's The Truth About the Drug Companies: How They Deceive Us and What
To Do About It,' Jerry Avorn's Powerful Medicines: The Benefits, Risks, and
2Costs of Prescription Drugs, Jerome Kassirer's On the Take: How America's
Complicity with Big Business Can Endanger Your Health,3 and John Abramson' s
Overdosed America: The Broken Promise of American Medicine.4 Thus, despite
a century of progress in developing safe and effective drugs that improve the
length and quality of life, we are left with a fundamental dissatisfaction over the
costs of medications and the rate of new drug development and innovation.
In November 2004, the University of Chicago's MacLean Center for
Clinical Medical Ethics, John M. Olin Program in Law and Economics at the
Law School, Committee on Clinical Pharmacology and Pharmacogenomics, and
* Lindy Bergman Distinguished Service Professor of Medicine and Surgery and Director,
MacLean Center for Clinical Medical Ethics, University of Chicago.
t University of Chicago Law School J.D. expected 2006, MacLean Center for Clinical
Medical Ethics.
f James Parker Hall Distinguished Service Professor of Law, The University of Chicago;
Peter and Kirsten Bedford Senior Fellow, The Hoover Institution.
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Harris Graduate School of Public Policy Studies convened scholars from
different disciplines to discuss these and related issues. The conference, titled
"Pharmaceutical Innovation and Cost: An American Dilemma," was held at the
Law School. A series of papers on innovation and regulation were presented at
the conference, some of which were selected for publication in this volume.
The first paper in the series, The Problem of New Uses by Professor Rebecca
Eisenberg,5 outlines the challenges our legal system faces when balancing the
social cost of data and product exclusivity against providing adequate incentives
for further research. In particular, she examines the need to promote corporate
research into new uses of existing drugs at a time when drug companies fear
negative results that call their drugs' safety into question (e.g. Cox-2 inhibitors)
and the prospect of generic manufacturers free-riding on data from new trials.
Eisenberg concludes that the best system would combine public disclosure of
data with extended product exclusivity, an intent she believes the FDA should
read into existing legislation. Professor Richard A. Epstein's paper, Regulatory
Paternalism in the Market for Drugs: Lessons from Vioxx and 
Celebrex,6
criticizes the FDA for a paternalistic regulatory approach that privileges the
safety of all potential drug users over informed individual choice. Epstein claims
that the FDA has strayed from its primary mission of protecting consumers
against impure substances and fraud. Epstein further argues that patients, not
regulatory agencies, are in the best position to assess what risks are acceptable,
and that the FDA's attempt to police the drug market solely through upstream
regulation shows indifference to the opportunity cost of denying treatment to
patients whose individual cost-benefit calculation counsels use of moderately
risky drugs.
Both Eisenberg and Epstein emphasize the economies of information at play
in the market for prescription drugs. The two final pieces, which examine aspects
of pharmaceutical advertising, provide additional perspectives on this theme. The
paper by Marshall Chin analyzes the way patients acquire information about
drugs in the burgeoning era of direct-to-consumer advertising (DTCA).7 The
period when patients received almost all of their information about which drugs
to take from their physicians has now passed. Although his paper, The Patient's
Role in Choice of Medications: Direct-to-Consumer Advertising and Patient
Decision Aids, concludes that DTCA is appropriate, Dr. Chin contends patients
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must diversify into other sources of information, including decision aids and
clinician guidance, to make optimal choices. In their paper The Effects and Role
of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative
Review, Puneet Manchanda and Elisabeth Honka look at the relationship between
detailing (informational sales pitches by drug company sales representatives to
physicians) and physician prescribing behavior.8 The authors aggregate data from
numerous empirical studies of detailing's impact on physician behavior and
conclude that detailing's impact is most significant early in a drug's life cycle,
but then declines as physicians gain access to other sources of information about
the drug.
At a time when the pharmaceutical industry finds itself the focus of
tremendous public attention, we hope that these papers offer some insight into
how the industry can best fulfill its promise of safe, innovative, and moderately-
priced drugs.
8. Puneet Manchanda & Elisabeth Honka, The Effects and Role of Direct-to-Physician
Marketing in the Pharmaceutical Industry: An Integrative Review, 5 YALE J. HEALTH POL'Y L. &
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